Theratechnologies announces US$11 million financing

On August 6, 2015, Theratechnologies Inc. closed a short-form prospectus offering of units which resulted in gross proceeds of $11,040,000. Euro Pacific Canada Inc. and Mackie Research Capital Corporation, the underwriters under the offering, exercised their over-allotment option prior to the closing of the offering, and a total of 4,600,000 units were issued. Each unit is comprised of one common share and one-half of a common share purchase warrant, at a price of $2.40 per unit. Each whole common share purchase warrant may be exercised until August 6, 2017, for an exercise price of $3.00. The common share purchase warrants were also listed on the Toronto Stock Exchange and now trade under the symbol TH.WT. The net proceeds of the Offering will likely be used for working capital purposes and for general corporate purposes, including the commercialization activities relating to Theratechnologies’ product, EGRIFTATM. Fasken Martineau advised Theratechnologies as part of the offering, with a team comprised of Robert Y. Girard, Sébastien Bellefleur, Monica Dingle, Joëlle Simard and Guillaume Saliah (securities) and Gilles Carli (tax).